| Q40468957 | 3 Kinetic factors that control the fate of thiyl radicals in cells |
| Q44071763 | A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury |
| Q33330520 | A risk-benefit assessment of amifostine in cytoprotection |
| Q73923837 | Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained |
| Q40677247 | Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector |
| Q34257881 | Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome |
| Q43364496 | Approaches to the prevention and management of radiation colitis |
| Q33607573 | Aspects on reducing gastrointestinal adverse effects associated with radiotherapy |
| Q33585345 | Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer |
| Q34316358 | Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis |
| Q35875388 | Combined modality therapy for rectal cancer. |
| Q40076594 | Current trends in the management of oral mucositis related to cancer treatment. |
| Q37157247 | Cytoprotective efficacy of amifostine against radiation- induced rectal toxicity: objective and subjective grading scales for radiomucositis. |
| Q78022255 | Effect of amifostine (Ethyol) on the development of extraembryonic blood vessels in chick embryos |
| Q28076526 | Endoscopic and non-endoscopic approaches for the management of radiation-induced rectal bleeding |
| Q36541213 | Gastrointestinal radiation injury: prevention and treatment |
| Q37780019 | Gastrointestinal toxicity associated to radiation therapy |
| Q34071798 | Has the outlook improved for amifostine as a clinical radioprotector? |
| Q40590819 | Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients |
| Q36495325 | Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score |
| Q89285911 | Management of Radiation Proctitis |
| Q35079602 | Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment |
| Q33789531 | Prevention of chronic radiation enteritis |
| Q40423962 | Protection of Normal Tissue from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine: Clinical Experiences |
| Q44493061 | Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial |
| Q73305359 | Radiation enteritis: sometimes the treatment is worse than the disease |
| Q39448990 | Radiation proctitis: current strategies in management |
| Q33991835 | Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis |
| Q43796427 | Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer |
| Q33178760 | Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group |
| Q42641434 | Recent advances in the management of radiation colitis |
| Q33502958 | Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer |
| Q33958507 | The potential role of amifostine in the treatment of non small cell lung cancer |
| Q41563195 | The role of adjuvant radiation therapy in the treatment of colorectal cancer |
| Q46222300 | The role of amifostine on late normal tissue damage induced by pelvic radiotherapy with concomitant gemcitabine: an in vivo study |
| Q33653212 | The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects |
| Q74617434 | [Late intestinal complications of adjuvant radiotherapy of rectal cancers] |
| Q38293704 | p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. |